source
- Lilly's mid‑stage weight‑loss trial looms as amylin design becomes a key differentiatorThe pharmaceutical community is watching a growing debate over how best to design amylin‑based medicines. Analysts say that the structural choices made by companies could determine which candidates…
- Merck partners with Sarah Cannon to accelerate community oncology trialsMerck & Co. has entered a collaboration with the Sarah Cannon Research Institute to expand patient access to oncology trials at community sites across the United States. The partnership will use S…